Abstract | BACKGROUND: METHODS: Mice were administered sodium selenite (2μg/g body weight) by gavage daily for 30days. Beginning on day 21, mice were administered 2.5% oral DSS for 9days. The mice were sacrificed on day 31. Survival rates, clinical symptoms, colon lengths, and histological changes were determined. RESULTS: CONCLUSIONS: Pretreatment with sodium selenite showed therapeutic potential for preventing colitis in mice. This effect may be mediated by the immunomodulation of regulatory T cells, expressing anti-inflammatory genes that suppress Th1 and Th17 responses.
|
Authors | Lixuan Sang, Bing Chang, Junfeng Zhu, Fangli Yang, Yan Li, Xuefeng Jiang, Xun Sun, Changlong Lu, Danan Wang |
Journal | International immunopharmacology
(Int Immunopharmacol)
Vol. 39
Pg. 359-368
(Oct 2016)
ISSN: 1878-1705 [Electronic] Netherlands |
PMID | 27533281
(Publication Type: Journal Article)
|
Copyright | Copyright © 2016. Published by Elsevier B.V. |
Chemical References |
- Forkhead Transcription Factors
- Foxp3 protein, mouse
- Interleukin-17
- Interleukin-10
- Interferon-gamma
- Dextran Sulfate
- Sodium Selenite
|
Topics |
- Acute Disease
- Animals
- Colitis
(chemically induced, drug therapy)
- Colon
(drug effects, pathology)
- Dextran Sulfate
- Forkhead Transcription Factors
(metabolism)
- Humans
- Interferon-gamma
(metabolism)
- Interleukin-10
(metabolism)
- Interleukin-17
(metabolism)
- Male
- Mice
- Mice, Inbred C57BL
- Models, Animal
- Sodium Selenite
(therapeutic use)
- T-Lymphocytes, Regulatory
(drug effects, immunology)
- Th1 Cells
(immunology)
- Th17 Cells
(immunology)
|